PE20190469A1 - Formulaciones, kits y metodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados - Google Patents
Formulaciones, kits y metodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentradosInfo
- Publication number
- PE20190469A1 PE20190469A1 PE2019000408A PE2019000408A PE20190469A1 PE 20190469 A1 PE20190469 A1 PE 20190469A1 PE 2019000408 A PE2019000408 A PE 2019000408A PE 2019000408 A PE2019000408 A PE 2019000408A PE 20190469 A1 PE20190469 A1 PE 20190469A1
- Authority
- PE
- Peru
- Prior art keywords
- masp
- amino acid
- formulation
- antibodies
- variable region
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 title abstract 3
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 title abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 101710199744 Anionic trypsin-2 Proteins 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- 101001056015 Homo sapiens Mannan-binding lectin serine protease 2 Proteins 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- 102000009112 Mannose-Binding Lectin Human genes 0.000 abstract 1
- 108010087870 Mannose-Binding Lectin Proteins 0.000 abstract 1
- 101710151381 Serine protease 2 Proteins 0.000 abstract 1
- 102100034392 Trypsin-2 Human genes 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 102000054960 human MASP2 Human genes 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se refiere a una formulacion estable y baja viscosidad de anticuerpos inhibidores de MASP-2 (serina proteasa -2 asociada a la lectina de union a manano) que comprende: (a) una solucion acuosa compuesta por un sistema de tampon de citrato o histidina con un pH de 5 a 7; (b) un anticuerpo monoclonal que se une especificamente al MASP-2 humano en una concentracion de 50mg/mL a 250 mg/mL, cuyo anticuerpo comprende: i) region variable de cadena pesada que comprende la secuencia de aminoacidos SEQ ID NO: 2, y ii) una region variable de cadena ligera que comprende la secuencia de aminoacidos SEQ ID NO: 3; y (c) un agente modificador de tonicidad es un aminoacido con una cadena lateral cargada negativamente, como el glutamato, entre otros; en cantidad suficiente para que la formulacion sea hipertonica. Dicha formulacion es util para inhibir los efectos adversos de la activacion del complemento dependiente de MASP-2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662382156P | 2016-08-31 | 2016-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190469A1 true PE20190469A1 (es) | 2019-04-04 |
Family
ID=61301617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019000408A PE20190469A1 (es) | 2016-08-31 | 2017-08-30 | Formulaciones, kits y metodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US11628217B2 (es) |
| EP (2) | EP4438060A2 (es) |
| JP (2) | JP6864747B2 (es) |
| KR (2) | KR20190043161A (es) |
| CN (3) | CN109890367B (es) |
| AR (1) | AR109494A1 (es) |
| AU (2) | AU2017321605B2 (es) |
| BR (1) | BR112019003479A2 (es) |
| CA (1) | CA3035252C (es) |
| CL (1) | CL2019000508A1 (es) |
| CO (1) | CO2019002239A2 (es) |
| CR (1) | CR20190150A (es) |
| CU (1) | CU20190015A7 (es) |
| DK (1) | DK3506886T3 (es) |
| EA (1) | EA201990598A1 (es) |
| EC (1) | ECSP19021312A (es) |
| FI (1) | FI3506886T3 (es) |
| GE (1) | GEP20217252B (es) |
| IL (1) | IL265071B2 (es) |
| JO (1) | JOP20170170B1 (es) |
| LT (1) | LT3506886T (es) |
| MA (1) | MA46109A (es) |
| MX (2) | MX2019002338A (es) |
| MY (1) | MY189411A (es) |
| PE (1) | PE20190469A1 (es) |
| PH (1) | PH12019500365A1 (es) |
| PT (1) | PT3506886T (es) |
| RS (1) | RS65845B1 (es) |
| SG (2) | SG10202100697PA (es) |
| SI (1) | SI3506886T1 (es) |
| TW (2) | TWI730310B (es) |
| UA (1) | UA122733C2 (es) |
| UY (1) | UY37391A (es) |
| WO (1) | WO2018045054A1 (es) |
| ZA (1) | ZA201901891B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201891570A1 (ru) * | 2016-01-05 | 2018-12-28 | Юниверсити Оф Лестер | Способ подавления фиброза у нуждающегося в этом субъекта |
| JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| JOP20190068A1 (ar) * | 2016-10-13 | 2019-04-01 | Omeros Corp | طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي |
| RU2020111574A (ru) * | 2017-08-25 | 2021-09-27 | Омерос Корпорейшн | Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом |
| MA55033A (fr) | 2019-02-18 | 2021-12-29 | Lilly Co Eli | Formulation d'anticorps thérapeutique |
| US20220273796A1 (en) * | 2019-07-19 | 2022-09-01 | Ichnos Sciences SA | Lyophilized antibody formulation |
| CN115335077A (zh) * | 2019-11-26 | 2022-11-11 | 奥默罗斯公司 | 用于治疗和/或预防与造血干细胞移植相关的特发性肺炎综合征（ips）和/或毛细血管渗漏综合征（cls）和/或植入综合征（es）和/或液体超负荷（fo）的方法 |
| IL293551A (en) | 2019-12-04 | 2022-08-01 | Omeros Corp | 2-masp inhibitor compounds, preparations containing them and their uses |
| JP2023504543A (ja) | 2019-12-04 | 2023-02-03 | オメロス コーポレーション | Ｍａｓｐ－２阻害剤および使用方法 |
| WO2021113686A1 (en) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| EP4069676A1 (en) | 2019-12-04 | 2022-10-12 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| US11912764B2 (en) | 2020-07-31 | 2024-02-27 | Alamab Therapeutics, Inc. | Anti-connexin antibody formulations |
| MX2023004533A (es) * | 2020-10-22 | 2023-07-05 | Allakos Inc | Formulaciones de anticuerpos anti-siglec-8. |
| JP2024523846A (ja) * | 2021-06-08 | 2024-07-02 | シャンハイ ジェミンケア ファーマシューティカル カンパニー，リミティド | 抗ｍａｓｐ－２抗体及びその使用 |
| EP4444758A2 (en) | 2021-12-10 | 2024-10-16 | Omeros Corporation | Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof |
| US20240228499A1 (en) | 2022-11-30 | 2024-07-11 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| WO2024140939A2 (zh) * | 2022-12-29 | 2024-07-04 | 苏州创胜医药集团有限公司 | 含有治疗性抗体的药物制剂及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| EP1962907A2 (en) | 2005-12-21 | 2008-09-03 | Wyeth a Corporation of the State of Delaware | Protein formulations with reduced viscosity and uses thereof |
| MX344322B (es) | 2009-10-16 | 2016-12-13 | Omeros Corp | Uso de una composición que comprende un agente inhibidor de masp-2 efectivo para inhibir o prevenir la aparición de agregados en la vaculatura de un sujeto que sufre de un desorden de coagulación mediado por complemento. |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| KR20180072851A (ko) * | 2011-04-08 | 2018-06-29 | 유니버시티 오브 레스터 | Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법 |
| US20150166676A1 (en) * | 2011-04-08 | 2015-06-18 | Omeros Corporation | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| MY188820A (en) * | 2011-05-02 | 2022-01-05 | Millennium Pharm Inc | Formulation for anti-?4?7 antibody |
| AU2012250627B2 (en) * | 2011-05-04 | 2016-01-07 | Omeros Corporation | Compositions for inhibiting MASP-2 dependent complement acitivation |
| KR20220100997A (ko) | 2012-06-18 | 2022-07-18 | 오메로스 코포레이션 | 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법 |
| WO2014141149A1 (en) | 2013-03-15 | 2014-09-18 | Glaxosmithkline Intellectual Property (No.2) Limited | Formulations with reduced viscosity |
| NZ757986A (en) | 2013-10-17 | 2022-07-29 | Omeros Corp | Methods for treating conditions associated with masp-2 dependent complement activation |
| SG11201701458YA (en) * | 2014-09-03 | 2017-03-30 | Medimmune Ltd | Stable anti-il-4r-alpha antibody formulation |
| JP2018500380A (ja) | 2014-12-31 | 2018-01-11 | ノベルメド セラピューティクス，インコーポレーテッド | アグリコシル化治療用抗体の製剤 |
| CA3004753C (en) | 2015-11-09 | 2023-02-28 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
| EA201891570A1 (ru) | 2016-01-05 | 2018-12-28 | Юниверсити Оф Лестер | Способ подавления фиброза у нуждающегося в этом субъекта |
| US20170253667A1 (en) | 2016-01-05 | 2017-09-07 | University Of Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
| CN117582494A (zh) | 2016-03-31 | 2024-02-23 | 奥默罗斯公司 | 抑制有需要的受试者的血管发生的方法 |
| JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
-
2017
- 2017-08-28 JO JOP/2017/0170A patent/JOP20170170B1/ar active
- 2017-08-29 TW TW108111015A patent/TWI730310B/zh active
- 2017-08-29 TW TW106129287A patent/TWI719245B/zh active
- 2017-08-30 RS RS20240925A patent/RS65845B1/sr unknown
- 2017-08-30 SI SI201731539T patent/SI3506886T1/sl unknown
- 2017-08-30 CA CA3035252A patent/CA3035252C/en active Active
- 2017-08-30 PT PT178474854T patent/PT3506886T/pt unknown
- 2017-08-30 MX MX2019002338A patent/MX2019002338A/es unknown
- 2017-08-30 EP EP24160975.9A patent/EP4438060A2/en active Pending
- 2017-08-30 AU AU2017321605A patent/AU2017321605B2/en active Active
- 2017-08-30 KR KR1020197008678A patent/KR20190043161A/ko not_active IP Right Cessation
- 2017-08-30 FI FIEP17847485.4T patent/FI3506886T3/fi active
- 2017-08-30 KR KR1020217035424A patent/KR102444154B1/ko active IP Right Grant
- 2017-08-30 BR BR112019003479-0A patent/BR112019003479A2/pt active Search and Examination
- 2017-08-30 DK DK17847485.4T patent/DK3506886T3/da active
- 2017-08-30 UA UAA201903034A patent/UA122733C2/uk unknown
- 2017-08-30 CU CU2019000015A patent/CU20190015A7/es unknown
- 2017-08-30 JP JP2019531596A patent/JP6864747B2/ja active Active
- 2017-08-30 SG SG10202100697PA patent/SG10202100697PA/en unknown
- 2017-08-30 WO PCT/US2017/049415 patent/WO2018045054A1/en active Application Filing
- 2017-08-30 CN CN201780051640.7A patent/CN109890367B/zh active Active
- 2017-08-30 CN CN202210971401.6A patent/CN116327695A/zh active Pending
- 2017-08-30 US US15/691,266 patent/US11628217B2/en active Active
- 2017-08-30 EP EP17847485.4A patent/EP3506886B1/en active Active
- 2017-08-30 EA EA201990598A patent/EA201990598A1/ru unknown
- 2017-08-30 MA MA046109A patent/MA46109A/fr unknown
- 2017-08-30 MY MYPI2019000424A patent/MY189411A/en unknown
- 2017-08-30 SG SG11201901444PA patent/SG11201901444PA/en unknown
- 2017-08-30 CN CN202210971376.1A patent/CN116327917A/zh active Pending
- 2017-08-30 GE GEAP201715038A patent/GEP20217252B/en unknown
- 2017-08-30 IL IL265071A patent/IL265071B2/en unknown
- 2017-08-30 CR CR20190150A patent/CR20190150A/es unknown
- 2017-08-30 PE PE2019000408A patent/PE20190469A1/es unknown
- 2017-08-30 LT LTEPPCT/US2017/049415T patent/LT3506886T/lt unknown
- 2017-08-31 UY UY0001037391A patent/UY37391A/es active IP Right Grant
- 2017-08-31 AR ARP170102432A patent/AR109494A1/es unknown
-
2019
- 2019-02-20 PH PH12019500365A patent/PH12019500365A1/en unknown
- 2019-02-26 MX MX2023014120A patent/MX2023014120A/es unknown
- 2019-02-26 CL CL2019000508A patent/CL2019000508A1/es unknown
- 2019-03-11 CO CONC2019/0002239A patent/CO2019002239A2/es unknown
- 2019-03-27 EC ECSENADI201921312A patent/ECSP19021312A/es unknown
- 2019-03-27 ZA ZA2019/01891A patent/ZA201901891B/en unknown
-
2020
- 2020-11-24 AU AU2020277135A patent/AU2020277135B2/en active Active
-
2021
- 2021-04-02 JP JP2021063245A patent/JP7197623B2/ja active Active
-
2023
- 2023-02-28 US US18/176,155 patent/US20230226178A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190469A1 (es) | Formulaciones, kits y metodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados | |
| PE20170780A1 (es) | Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf | |
| PE20141159A1 (es) | Metodos para tratar o prevenir trastornos relacionados con el colesterol | |
| AR108317A1 (es) | Composiciones que comprenden coformulación de anticuerpos anti-pd-l1 y anti-ctla-4 | |
| AR111773A1 (es) | Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración | |
| CR20190400A (es) | Formulaciones de anticuerpo monoclonal anti-vrs | |
| PE20181889A1 (es) | Preparaciones que contienen anticuerpos | |
| AR111455A1 (es) | Formulación estable de anticuerpo | |
| PE20200513A1 (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso | |
| AR107014A1 (es) | Formulación farmacéutica acuosa | |
| CL2020002012A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032) | |
| AR097791A1 (es) | Formulaciones de anticuerpos anti-pdl1 | |
| BR112018002196A2 (pt) | formulação anti-ifnar1 estável | |
| AR080428A1 (es) | Formulaciones liquidas estabilizadas contentivas de anticuerpos | |
| AR087305A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit | |
| NZ705178A (en) | Anti-prolactin receptor antibody formulations | |
| AR095396A1 (es) | Formulaciones de anticuerpo | |
| CL2018003178A1 (es) | Composición farmacéutica | |
| PE20151524A1 (es) | FORMULACIONES DE LA SOLUCION DE LOS ANTICUERPOS ANTI-IL-23p19 MANIPULADOS GENETICAMENTE | |
| AU2019339740A8 (en) | CSF-1R antibody formulation | |
| AR091530A1 (es) | Formulacion farmaceutica liquida de un anticuerpo y acetato | |
| AR096705A1 (es) | Composición que comprende ácido glutámico-n,n-diacetato (glda), agua y enzima | |
| CL2021001587A1 (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| CO2021015561A2 (es) | Formulaciones de anticuerpo de baja viscosidad, estables y usos de las mismas | |
| AR115713A1 (es) | FORMULACIÓN ESTABLE DE ALTA CONCENTRACIÓN PARA ANTICUERPOS ANTI-FXIa |